Perioperative Fostamatinib for Resectable Pancreatic Cancer
This study is looking at a new way to treat pancreatic cancer that can be removed by surgery. It combines Fostamatinib, a drug approved for a different blood condition, with standard chemotherapy drugs, gemcitabine and nab-paclitaxel. Researchers believe Fostamatinib might help the body's immune system fight the cancer. You might be able to join if you are at least 18 years old, have pancreatic cancer that can be surgically removed, and have a good performance status (meaning you can do most daily activities). The main goal of this study is to see if Fostamatinib with chemotherapy delays surgery. The current recruitment status is unclear.
- Study design
- This is a Phase 1b interventional study planning to enroll 36 participants. It is not specified if it is randomized or blinded.
- What's involved
- You will receive 4 cycles of treatment before surgery, followed by surgery, and then 2 cycles of treatment after surgery. You will be followed for up to 2 years after joining the study.
- Compensation
- Not stated in the trial record.
- Follow-up
- Participants will be followed long-term until death or for 2 years after enrollment, whichever comes first.
AI-generated from the public study record. Only the study team can confirm whether you're eligible — confirm details with them before making decisions.
Perioperative Fostamatinib With Gemcitabine and Nab-paclitaxel in Resectable Pancreatic Cancer
At a glance
Conditions
NCT06639724
Where you'd take part
This study runs at 1 site. They're the same protocol — you choose where, and that choice sets who your contact draft is addressed to.
University of California, San Diego Moores Cancer Center
La Jolla, Californiastudy coordinator listed
Recruiting
Sites open and close at different times, so the status above is per site — it can differ from the study's overall status.
Study leadership
- Andrew Lowy, MD · STUDY_CHAIR · UCSD
Who to contact
Opens a ready-to-send draft in your own email app — review before sending.
What this trial measures
- Surgical delay6 weeks from the last pre-operative treatment cycle
Number and percentage of participants who experience surgical delay, as measured by the proportion of enrolled participants for whom pancreatic resection cannot be performed within 6 weeks of the last pre-operative treatment cycle.